Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients
N. V. Chichkova, S. I. Ovtcharenko, Y. M. Ovchinnikov, V. A. Gumenyuk (Moscow, Russia)
Source: Annual Congress 2002 - Asthma - Therapy and management -2
Session: Asthma - Therapy and management -2
Session type: Thematic Poster Session
Number: 400
Disease area: Airway diseases
Abstract Our objective was to compare efficacy and safety of Mometasone furoate, nasal spray (MF), and Zafirlukast (Z) in treatment of patients (pts) with nasal polyps (NP) and mild-to-moderate asthma (A). A total of 48 pts (28 m and 20 f; FEV1pred from 60 to 79%) were randomized into two groups. The pts were observed from 2 to 24 weeks. Patients in Group I (22) were treated with daily 200 mcg MF; basic therapy of A (corticosteroid inhalations) depended on its severity (GINA). Group II pts (26) were given Z as monotherapy (40 mg/day). NP symptoms subsided in Group I in 2 weeks: nasal breathing was restored in 16 pts (72.7%); according to rhinomanometry, nasal air flow increased (p<0.01). Nasal endoscopy showed diminished edema of the nasal mucosa; polyps shrunk to [onehalf] their volume. Positive effect in Group II was obvious not earlier than in 4 weeks of treatment: nasal breathing was restored in 14 pts (53.8%); nasal endoscopy revealed reduction of polyps by an average of [onehalf] their volume. Eosinophil count in nasal lavage fluid (NLF) decreased (p<0.01) in two groups. NP symptoms did not respond to a 4-week treatment in 4 pts of Group I and 5 pts of Group II. Conclusion: Early positive effect of MF treatment was noted in pts with confirmed atopy, high initial serum IgE and large number of eosonophils in NLF. NP sypmtoms changed markedly in aspirin-sensitive pts treated with Z. A 24-week observation confirmed good tolerance and safety of MF and Z.
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. V. Chichkova, S. I. Ovtcharenko, Y. M. Ovchinnikov, V. A. Gumenyuk (Moscow, Russia). Comparative effects of Mometason furoate and Zafirlukast in treatment of nasal polyps in asthmatic patients. Eur Respir J 2002; 20: Suppl. 38, 400
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Additive effect of Zafirlukast in combination with Mometason furoate in treatment of Nasal polyps in patients with mild persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 372s Year: 2003
Efficacy of mometasone furoate in patients with mild-to-moderate asthma: lack of gender-specific effects Source: Eur Respir J 2001; 18: Suppl. 33, 96s Year: 2001
Efficiency of once-daily mometasone furoate in school children with seasonal allergic rhinitis and severe nasal congestion Source: Eur Respir J 2006; 28: Suppl. 50, 664s Year: 2006
A comparison of fluticasone propionate (FP) and mometasone furoate (MF) nasal spray in the treatment of nasal polyposis associated with asthma Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Treatment with inhaled steroids in patients with symptoms suggestive of asthma but with normal lung function Source: Eur Respir J 2008; 32: 989-996 Year: 2008
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Anti-inflammatory effect and clinical efficacy of concomitant treatments to steroid inhaler in bronchial asthma: montelukast versus salmeterol Source: Eur Respir J 2006; 28: Suppl. 50, 315s Year: 2006
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Mometasone furoate nasal spray compared with loradatine in school children with seasonal allergic rhinitis Source: Annual Congress 2010 - Managing asthma and allergic disease in children Year: 2010
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
The effect of fluticasone vs fluticasone plus salmeterol on allergen-induced bronchial inflammation in asthmatic patients. A long-term RCT Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Early treatment of perennial rhinitis with budesonide or cetirizine: effect on nasal inflammation Source: Eur Respir J 2002; 20: Suppl. 38, 92s Year: 2002
Effect of the addition of montelukast to inhaled fluticasone propionate on immunopathology in bronchial biopsies from mild to moderate asthmatics Source: Eur Respir J 2002; 20: Suppl. 38, 388s Year: 2002
Zafirlukast versus budesonide on bronchial reactivity in subjects with mild-persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 263s Year: 2001
The effects of fluticasone propionate in asthmatic patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Indacaterol/glycopyrronium/mometasone furoate combination consistently shows lung function benefits in patients with asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019
Efficacy and systemic effects of ciclesonide and fluticasone in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 147s Year: 2001
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma Source: Eur Respir J 2002; 20: 66-72 Year: 2002
Efficacy and safety of ciclesonide compared with fluticasone propionate or budesonide in adolescent patients with persistent asthma Source: Eur Respir J 2007; 30: Suppl. 51, 458s Year: 2007
Effects of inhaled corticosteroids on growth in asthmatic children: A comparision of fluticasone propianate with budesonide Source: Eur Respir J 2003; 22: Suppl. 45, 133s Year: 2003